GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Minerva Neurosciences Inc (NAS:NERV) » Definitions » EV-to-EBITDA

NERV (Minerva Neurosciences) EV-to-EBITDA : -3.19 (As of Dec. 14, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Minerva Neurosciences EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Minerva Neurosciences's enterprise value is $-11.07 Mil. Minerva Neurosciences's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $3.47 Mil. Therefore, Minerva Neurosciences's EV-to-EBITDA for today is -3.19.

The historical rank and industry rank for Minerva Neurosciences's EV-to-EBITDA or its related term are showing as below:

NERV' s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.59   Med: -6.55   Max: 60.48
Current: -3.19

During the past 12 years, the highest EV-to-EBITDA of Minerva Neurosciences was 60.48. The lowest was -10.59. And the median was -6.55.

NERV's EV-to-EBITDA is ranked better than
99.56% of 452 companies
in the Biotechnology industry
Industry Median: 9.27 vs NERV: -3.19

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-12-14), Minerva Neurosciences's stock price is $2.21. Minerva Neurosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.450. Therefore, Minerva Neurosciences's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Minerva Neurosciences EV-to-EBITDA Historical Data

The historical data trend for Minerva Neurosciences's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minerva Neurosciences EV-to-EBITDA Chart

Minerva Neurosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.07 35.30 0.59 1.12 -0.10

Minerva Neurosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.10 0.73 0.35 -2.26

Competitive Comparison of Minerva Neurosciences's EV-to-EBITDA

For the Biotechnology subindustry, Minerva Neurosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minerva Neurosciences's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Minerva Neurosciences's EV-to-EBITDA falls into.



Minerva Neurosciences EV-to-EBITDA Calculation

Minerva Neurosciences's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-11.073/3.469
=-3.19

Minerva Neurosciences's current Enterprise Value is $-11.07 Mil.
Minerva Neurosciences's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Minerva Neurosciences  (NAS:NERV) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Minerva Neurosciences's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.21/-0.450
=At Loss

Minerva Neurosciences's share price for today is $2.21.
Minerva Neurosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.450.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Minerva Neurosciences EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Minerva Neurosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Minerva Neurosciences Business Description

Traded in Other Exchanges
Address
1500 District Avenue, Burlington, MA, USA, 01803
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Executives
Ag Boehringer 10 percent owner BINGER STRABE 173, INGELHEIM AM RHEIN 2M 55216
Boehringer Ingelheim International Gmbh 10 percent owner 200 PARK AVENUE, C/O KLAUS H JANDER ESQ ROGERS & WELLS LL, NEW YORK NY 10166
Remy Luthringer officer: EVP and Head of R&D C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Geoff Race officer: EVP and CFO C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Frederick W Ahlholm officer: Chief Accounting Officer C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
David Kupfer director C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Joseph H. Reilly officer: Chief Business Officer C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Van Heek G Jan director ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Richard E. Russell officer: President C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
William F Doyle director
Hans Peter Hasler director C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Index Venture Associates Iii Ltd 10 percent owner 5TH FLOOR, 44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE1 3FG
Index Venture Associates Iv Ltd 10 percent owner 44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE4 9WG